Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial

Affiliations

¹ Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
² Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK. Electronic address: natasha.hezelgrave@nhs.net.

Comment

Imogen Bacon et al. Lancet. 2024.

. 2024 Aug 24;404(10454):750-751.

doi: 10.1016/S0140-6736(24)01513-7.

¹ Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
² Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK. Electronic address: natasha.hezelgrave@nhs.net.

No abstract available

Comment in

Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
Figueras F, Rial-Crestelo M, Gratacos E. Figueras F, et al. Lancet. 2024 Aug 24;404(10454):751-752. doi: 10.1016/S0140-6736(24)01514-9. Lancet. 2024. PMID: 39181594 No abstract available.

Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
Rial-Crestelo M, Lubusky M, Parra-Cordero M, Krofta L, Kajdy A, Zohav E, Ferriols-Perez E, Cruz-Martinez R, Kacerovsky M, Scazzocchio E, Roubalova L, Socias P, Hašlík L, Modzelewski J, Ashwal E, Castellá-Cesari J, Cruz-Lemini M, Gratacos E, Figueras F; RATIO37 Study Group. Rial-Crestelo M, et al. Lancet. 2024 Feb 10;403(10426):545-553. doi: 10.1016/S0140-6736(23)02228-6. Epub 2024 Jan 11. Lancet. 2024. PMID: 38219773 Clinical Trial.